Peter Wehrwein, Managing Editor

Data from week 156 are favorable and no new safety signals emerged, says researcher.

Fluid resolution at week 4 seems to translate into longer dosing intervals at week 96 of the PULSAR trial that assessed Eylea HD in patients with neovascular (wet) age-related macular degeneration.

Results show dosing intervals increasing by two weeks or longer for patients with diabetic macular edema and neovascular (wet) age-related macular degeneration who switch to Eylea HD.

Extension study results suggest dosing intervals of 20 weeks or more for Eylea HD for diabetic macular edema.

New insights emerge from ongoing analyses of GA studies, enhancing AMD treatment strategies and patient management at Bay Area Retina Associates.

Discover new safety insights on Syfovre for geographic atrophy treatment, as Roger A. Goldberg highlights promising long-term data at ASRS 2025.

New findings reveal Syfovre may protect central vision in macular degeneration patients, delaying vision loss and enhancing treatment strategies.

New findings reveal that early treatment with Syfovre significantly improves vision preservation in geographic atrophy patients, according to Robert Goldberg, M.D., MBA, of the Bay Area Retina Associates.

Cigna has sold its Medicare businesses and slashed the number of people it covers in its ACA plans by more than half.

Interest in surgical advancements such as retinal detachment repair is driven by the need for balance within the field and a new generation entering the workforce, according to Gaurav K. Shah, M.D., program chair of ASRS 2025.

A session on a surgery technique to treat macular holes using amniotic membrane transplants will be one of the highlights at the 2025 meeting of the American Society of Retina Specialists, according to Gaurav K. Shah, M.D., program chair of ASRS 2025.

There will be a greater focus on surgical topics at the 2025 meeting of the American Society of Retina Specialists, compared with previous years, which reflects the need for balance within the industry, according to Gaurav K. Shah, M.D., program chair of ASRS 2025.

Surveys of American Society of Retina Specialists members have revealed a preference for physicians’ experiences with new therapies, rather than summaries of clinical trial data, according to Gaurav K. Shah, M.D., program chair of ASRS 2025.

The company's strong performance is due in part to increased revenue fro, pharmacy benefit services business.

Company officials say they are focusing on "more disciplined managed products" as they prepare to exit PPOs in 2026 that currently cover 800,000 members, including 600,000 people enrolled in Medicare Advantage plans.

The healthcare conglomerate says rising medical costs are squeezing earnings from operations.

Long-acting injectable PrEP may improve access, protection and adherence, especially for young people and pregnant women, according to Hasina Subedar, a senior technical advisor at South Africa’s National Department of Health, who spoke with editors at IAS 2025 in Kigali, Rwanda.

A monthly pill would add to the growing number of choices for HIV preexposure prophylaxis, which is now seen as the best hope for curbing the number of new infections.

A larger role for China, perhaps, and the fraught issue of integrating HIV services into services for other diseases.

Experts, such as Lloyd Mulenga, M.Sc., M.B., Ch.B., Ph.D., discuss long-acting injectable HIV PrEP's potential in Zambia, emphasizing community involvement and sustainable rollout amid funding challenges.

The use of preexposure prophylaxis lags far behind a 2025 target of 21.2 million people.

Alarice Marsh, M.P.H., a deputy director in the National Department of Health of South Africa and program lead of HIV testing services, spoke with MHE editors about her thoughts on the new recommendations for HIV and sexually transmitted diseases that were issued by the World Health Organization (WHO) today.

A World Health official says there wasn’t enough evidence at this point to support a recommendation.

But 25 low- and middle-income countries have responded with plans for increased allocation of HIV funds, says the UNAIDS executive director. "...countries, governments and civil society are not lying down and waiting to die..."

“Millions of lives and decades of progress hang in the balance,” says the president of the International AIDS Society (IAS) during a premeeting press conference.

Peripheral blood stem cell transplants are safer and easier for the donor and with contemporary graft-vs-host disease (GVHD) prophylaxis, they don't appear to pose any additional GVHD risk for the recipient.